Review ArticleReview Article
Open Access

Clostridioides (Clostridium) difficile

A silent nosocomial pathogen

Ibrahim A. Al-Zahrani
Saudi Medical Journal September 2023, 44 (9) 825-835; DOI: https://doi.org/10.15537/smj.2023.44.9.20230216

References

  1. 1.↵
    1. Vonberg RP,
    2. Kuijper EJ,
    3. Wilcox MH,
    4. Barbut F,
    5. Tüll P,
    6. Gastmeier P, et al.
    Infection control measures to limit the spread of Clostridium difficile. Clin Microbiol Infect 2008; 14: 2–20.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    1. Spigaglia P,
    2. Mastrantonio P,
    3. Barbanti F.
    Antibiotic resistances of Clostridium difficile. Adv Exp Med Biol 2018; 1050: 137–159.
    OpenUrl
  3. 3.↵
    1. Borriello SP.
    Pathogenesis of Clostridium difficile infection. J Antimicrob Chemother 1998; 41: 13–19.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    1. Kuijper EJ,
    2. Coignard B,
    3. Tüll P.
    Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 2006; 12: 2–18.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Goorhuis A,
    2. Bakker D,
    3. Corver J,
    4. Debast SB,
    5. Harmanus C,
    6. Notermans DW, et al.
    Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis 2008; 47: 1162–1170.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    1. Bolton D,
    2. Marcos P.
    The environment, farm animals and foods as sources of Clostridioides difficile infection in humans. Foods 2023; 12: 1094.
    OpenUrl
  7. 7.↵
    1. Weese JS.
    Clostridium (Clostridioides) difficile in animals. J Vet Diagn Invest 2020; 32: 213–221.
    OpenUrl
  8. 8.↵
    1. Carroll KC,
    2. Mizusawa M.
    Laboratory tests for the diagnosis of Clostridium difficile. Clin Colon Rectal Surg 2020; 33: 73–81.
    OpenUrl
  9. 9.↵
    1. Kraft CS,
    2. Parrott JS,
    3. Cornish NE,
    4. Rubinstein ML,
    5. Weissfeld AS,
    6. McNult P, et al.
    A laboratory medicine best practices systematic review and meta-analysis of nucleic acid amplification tests (NAATs) and algorithms including NAATs for the diagnosis of Clostridioides (Clostridium) difficile in adults. Clin Microbiol Rev 2019; 32: e00032–e00018.
    OpenUrl
  10. 10.↵
    1. Mayfield JL,
    2. Leet T,
    3. Miller J,
    4. Mundy LM.
    Environmental control to reduce transmission of Clostridium difficile. Clin Infect Dis 2000; 31: 995–1000.
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    1. Hall IC,
    2. O’Toole E.
    Intestinal flora in new-born infants with a description of a new pathogenic anaerobe, bacillus difficilis. Am J Dis Child 1935; 49: 390–402.
    OpenUrlCrossRef
  12. 12.
    1. Montoya A,
    2. Mody L.
    Common infections in nursing homes: a review of current issues and challenges. Aging health 2011; 7: 889–899.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Heinlen L,
    2. Ballard JD.
    Clostridium difficile infection. Am J Med Sci 2010; 340: 247–252.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Tedesco FJ,
    2. Barton RW,
    3. Alpers DH.
    Clindamycin-associated colitis. A prospective study. Ann Intern Med 1974; 81: 429–433.
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.↵
    1. Bartlett JG.
    Clostridium difficile infection: historic review. Anaerobe 2009; 15: 227–229.
    OpenUrlPubMed
  16. 16.↵
    1. Larson HE,
    2. Price AB.
    Pseudomembranous colitis: presence of clostridial toxin. Lancet 1977; 2: 1312–1314.
    OpenUrlPubMedWeb of Science
  17. 17.↵
    1. Bartlett JG,
    2. Chang TW,
    3. Gurwith M,
    4. Gorbach SL,
    5. Onderdonk AB.
    Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med 1978; 298: 531–534.
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    1. Burnham CA,
    2. Carroll KC.
    Diagnosis of Clostridium difficile infection: an ongoing conundrum for clinicians and for clinical laboratories. Clin Microbiol Rev 2013; 26: 604–630.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Smits WK,
    2. Lyras D,
    3. Lacy DB,
    4. Wilcox MH,
    5. Kuijper EJ.
    Clostridium difficile infection. Nat Rev Dis Primers 2016; 2: 16020.
    OpenUrl
  20. 20.↵
    1. Leffler DA,
    2. Lamont JT.
    Clostridium difficile Infection. N Engl J Med 2015; 373: 287–288.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Denève C,
    2. Janoir C,
    3. Poilane I,
    4. Fantinato C,
    5. Collignon A.
    New trends in Clostridium difficile virulence and pathogenesis. Int J Antimicrob Agents 2009; 33: S24–S28.
    OpenUrlCrossRefPubMed
  22. 22.
    1. Ling Z,
    2. Liu X,
    3. Jia X,
    4. Cheng Y,
    5. Luo Y,
    6. Yuan L, et al.
    Impacts of infection with different toxigenic Clostridium difficile strains on faecal microbiota in children. Sci Rep 2014; 4: 7485.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Lyras D,
    2. O’Connor JR,
    3. Howarth PM,
    4. Sambol SP,
    5. Carter GP,
    6. Phumoonna T, et al.
    Toxin B is essential for virulence of Clostridium difficile. Nature 2009; 458: 1176–1179.
    OpenUrlCrossRefPubMedWeb of Science
  24. 24.↵
    1. Janoir C.
    Virulence factors of Clostridium difficile and their role during infection. Anaerobe 2016; 37: 13–24.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Czepiel J,
    2. Dróżdż M,
    3. Pituch H,
    4. Kuijper EJ,
    5. Perucki W,
    6. Mielimonka A, et al.
    Clostridium difficile infection: review. Eur J Clin Microbiol Infect Dis 2019; 38: 1211–1221.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Peng Z,
    2. Jin D,
    3. Kim HB,
    4. Stratton CW,
    5. Wu B,
    6. Tang YW, et al.
    Update on antimicrobial resistance in Clostridium difficile: resistance mechanisms and antimicrobial susceptibility testing. J Clin Microbiol 2017; 55: 1998–2008.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Debast SB,
    2. Bauer MP,
    3. Kuijper EJ.
    European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 2014; 20: 1–26.
    OpenUrlCrossRefPubMed
  28. 28.
    1. Petrosillo N,
    2. Granata G,
    3. Cataldo MA.
    Novel antimicrobials for the treatment of Clostridium difficile infection. Front Med (Lausanne) 2018; 5: 96.
    OpenUrl
  29. 29.↵
    1. Johnson S,
    2. Lavergne V,
    3. Skinner AM,
    4. Gonzales-Luna AJ,
    5. Garey KW,
    6. Kelly CP, et al.
    Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults. Clin Infect Dis 2021; 73: 755–757.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Spigaglia P.
    Recent advances in the understanding of antibiotic resistance in Clostridium difficile infection. Ther Adv Infect Dis 2016; 3: 23–42.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Tkhawkho L,
    2. Nitzan O,
    3. Pastukh N,
    4. Brodsky D,
    5. Jackson K,
    6. Peretz A.
    Antimicrobial susceptibility of Clostridium difficile isolates in Israel. J Glob Antimicrob Resist 2017; 10: 161–164.
    OpenUrl
  32. 32.↵
    1. Banawas SS.
    Clostridium difficile infections: a global overview of drug sensitivity and resistance mechanisms. Biomed Res Int 2018; 2018: 8414257.
    OpenUrl
  33. 33.↵
    1. Dilnessa T,
    2. Getaneh A,
    3. Hailu W,
    4. Moges F,
    5. Gelaw B.
    Prevalence and antimicrobial resistance pattern of Clostridium difficile among hospitalized diarrheal patients: a systematic review and meta-analysis. PLoS One 2022; 17: e0262597.
    OpenUrl
  34. 34.↵
    1. O’Grady K,
    2. Knight DR,
    3. Riley TV.
    Antimicrobial resistance in Clostridioides difficile. Eur J Clin Microbiol Infect Dis 2021; 40: 2459–2478.
    OpenUrl
  35. 35.↵
    1. Tickler IA,
    2. Goering RV,
    3. Whitmore JD,
    4. Lynn AN,
    5. Persing DH,
    6. Tenover FC.
    Strain types and antimicrobial resistance patterns of Clostridium difficile isolates from the United States, 2011-2013. Antimicrob Agents Chemother 2014; 58: 4214–4218.
    OpenUrlAbstract/FREE Full Text
  36. 36.↵
    1. Mutai WC,
    2. Mureithi MW,
    3. Anzala O,
    4. Revathi G,
    5. Kullin B,
    6. Burugu M, et al.
    High prevalence of multidrug-resistant Clostridioides difficile following extensive use of antimicrobials in hospitalized patients in Kenya. Front Cell Infect Microbiol 2021; 10: 604986.
    OpenUrl
  37. 37.
    1. Rodríguez-Pardo D,
    2. Almirante B,
    3. Bartolomé RM,
    4. Pomar V,
    5. Mirelis B,
    6. Navarro F, et al.
    Epidemiology of Clostridium difficile infection and risk factors for unfavorable clinical outcomes: results of a hospital-based study in Barcelona, Spain. J Clin Microbiol 2013; 51: 1465–1473.
    OpenUrlAbstract/FREE Full Text
  38. 38.
    1. Dong D,
    2. Zhang L,
    3. Chen X,
    4. Jiang C,
    5. Yu B,
    6. Wang X, et al.
    Antimicrobial susceptibility and resistance mechanisms of clinical Clostridium difficile from a Chinese tertiary hospital. Int J Antimicrob Agents 2013; 41: 80–84.
    OpenUrlCrossRefPubMed
  39. 39.↵
    1. Huang H,
    2. Fang H,
    3. Weintraub A,
    4. Nord CE.
    Distinct ribotypes and rates of antimicrobial drug resistance in Clostridium difficile from Shanghai and Stockholm. Clin Microbiol Infect 2009; 15: 1170–1173.
    OpenUrlCrossRefPubMedWeb of Science
  40. 40.↵
    1. Isidro J,
    2. Menezes J,
    3. Serrano M,
    4. Borges V,
    5. Paixão P,
    6. Mimoso M, et al.
    Genomic study of a Clostridium difficile multidrug resistant outbreak-related clone reveals novel determinants of resistance. Front Microbiol 2018; 9: 2994.
    OpenUrl
  41. 41.↵
    1. Chow VCY,
    2. Kwong TNY,
    3. So EWM,
    4. Ho YII,
    5. Wong SH,
    6. Lai RWM, et al.
    Surveillance of antibiotic resistance among common Clostridium difficile ribotypes in Hong Kong. Sci Rep 2017; 7: 17218.
    OpenUrl
  42. 42.↵
    1. Sholeh M,
    2. Krutova M,
    3. Forouzesh M,
    4. Mironov S,
    5. Sadeghifard N,
    6. Molaeipour L, et al.
    Antimicrobial resistance in Clostridioides (Clostridium) difficile derived from humans: a systematic review and meta-analysis. Antimicrob Resist Infect Control 2020; 9: 158.
    OpenUrl
  43. 43.↵
    1. Krutova M,
    2. Matejkova J,
    3. Tkadlec J,
    4. Nyc O.
    Antibiotic profiling of Clostridium difficile ribotype 176--A multidrug resistant relative to C. difficile ribotype 027. Anaerobe 2015; 36: 88–90.
    OpenUrl
  44. 44.↵
    1. Sebaihia M,
    2. Wren BW,
    3. Mullany P,
    4. Fairweather NF,
    5. Minton N,
    6. Stabler R, et al.
    The multidrug-resistant human pathogen Clostridium difficile has a highly mobile, mosaic genome. Nat Genet 2006; 38: 779–786.
    OpenUrlCrossRefPubMedWeb of Science
  45. 45.↵
    1. Knight DR,
    2. Squire MM,
    3. Collins DA,
    4. Riley TV.
    Genome analysis of Clostridium difficile PCR ribotype 014 lineage in Australian pigs and humans reveals a diverse genetic repertoire and signatures of long-range interspecies transmission. Front Microbiol 2017; 7: 2138.
    OpenUrlCrossRef
  46. 46.
    1. Scaria J,
    2. Ponnala L,
    3. Janvilisri T,
    4. Yan W,
    5. Mueller LA,
    6. Chang YF.
    Analysis of ultra low genome conservation in Clostridium difficile. PLoS One 2010; 5: e15147.
    OpenUrlCrossRefPubMed
  47. 47.
    1. Knight DR,
    2. Kullin B,
    3. Androga GO,
    4. Barbut F,
    5. Eckert C,
    6. Johnson S, et al.
    Evolutionary and genomic insights into Clostridioides difficile sequence type 11: a diverse zoonotic and antimicrobial-resistant lineage of global one health importance. mBio 2019; 10: e00446–e00419.
    OpenUrl
  48. 48.↵
    1. Kulecka M,
    2. Waker E,
    3. Ambrozkiewicz F,
    4. Paziewska A,
    5. Skubisz K,
    6. Cybula P, et al.
    Higher genome variability within metabolism genes associates with recurrent Clostridium difficile infection. BMC Microbiol 2021; 21: 36.
    OpenUrl
  49. 49.↵
    1. Knight DR,
    2. Elliott B,
    3. Chang BJ,
    4. Perkins TT,
    5. Riley TV.
    Diversity and evolution in the genome of Clostridium difficile. Clin Microbiol Rev 2015; 28: 721–741.
    OpenUrlAbstract/FREE Full Text
  50. 50.
    1. Sommermeyer H,
    2. Piątek J.
    Clostridioides difficile: infections, risk factors, prevention and treatment. [Updated 2021; 2022 Dec 20]. Available from: https://link.springer.com/book/10.1007/978-3-030-81100-6
  51. 51.↵
    1. Crobach MJT,
    2. Vernon JJ,
    3. Loo VG,
    4. Kong LY,
    5. Péchiné S,
    6. Wilcox MH, et al.
    Understanding Clostridium difficile colonization. Clin Microbiol Rev 2018; 31: e00021–e00017.
    OpenUrlCrossRefPubMed
  52. 52.↵
    1. Schäffler H,
    2. Breitrück A.
    Clostridium difficile - from colonization to infection. Front Microbiol 2018; 9: 646.
    OpenUrlCrossRef
  53. 53.↵
    1. Furuya-Kanamori L,
    2. Marquess J,
    3. Yakob L,
    4. Riley TV,
    5. Paterson DL,
    6. Foster NF, et al.
    Asymptomatic Clostridium difficile colonization: epidemiology and clinical implications. BMC Infect Dis 2015; 15: 516.
    OpenUrlCrossRef
  54. 54.↵
    1. Shin JH,
    2. Chaves-Olarte E,
    3. Warren CA.
    Clostridium difficile infection. Microbiol Spectr 2016; 4: 10.
    OpenUrl
  55. 55.↵
    1. Martinez E,
    2. Taminiau B,
    3. Rodriguez C,
    4. Daube G.
    Gut microbiota composition associated with Clostridioides difficile colonization and infection. Pathogens 2022; 11: 781.
    OpenUrl
  56. 56.↵
    1. Rousseau C,
    2. Poilane I,
    3. De Pontual L,
    4. Maherault AC,
    5. Le Monnier A,
    6. Collignon A.
    Clostridium difficile carriage in healthy infants in the community: a potential reservoir for pathogenic strains. Clin Infect Dis 2012; 55: 1209–1215.
    OpenUrlCrossRefPubMed
  57. 57.↵
    1. Baban ST,
    2. Kuehne SA,
    3. Barketi-Klai A,
    4. Cartman ST,
    5. Kelly ML,
    6. Hardie KR, et al.
    The role of flagella in Clostridium difficile pathogenesis: comparison between a non-epidemic and an epidemic strain. PLoS One 2013; 8: e73026.
    OpenUrlCrossRefPubMed
  58. 58.↵
    1. Awad MM,
    2. Johanesen PA,
    3. Carter GP,
    4. Rose E,
    5. Lyras D.
    Clostridium difficile virulence factors: insights into an anaerobic spore-forming pathogen. Gut Microbes 2014; 5: 579–593.
    OpenUrlCrossRef
  59. 59.↵
    1. Bauer MP,
    2. Notermans DW,
    3. van Benthem BH,
    4. Brazier JS,
    5. Wilcox MH,
    6. Rupnik M, et al.
    Clostridium difficile infection in Europe: a hospital-based survey. Lancet 2011; 377: 63–73.
    OpenUrlCrossRefPubMedWeb of Science
  60. 60.↵
    1. Freeman J,
    2. Bauer MP,
    3. Baines SD,
    4. Corver J,
    5. Fawley WN,
    6. Goorhuis B, et al.
    The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev 2010; 23: 529–549.
    OpenUrlAbstract/FREE Full Text
  61. 61.↵
    1. Lanis JM,
    2. Heinlen LD,
    3. James JA,
    4. Ballard JD.
    Clostridium difficile 027/BI/NAP1 encodes a hypertoxic and antigenically variable form of TcdB. PLoS Pathog 2013; 9: e1003523.
    OpenUrlCrossRefPubMed
  62. 62.↵
    1. Popoff MR,
    2. Rubin EJ,
    3. Gill DM,
    4. Boquet P.
    Actin-specific ADP-ribosyltransferase produced by a Clostridium difficile strain. Infect Immun 1988; 56: 2299–2306.
    OpenUrlAbstract/FREE Full Text
  63. 63.↵
    1. Valiente E,
    2. Cairns MD,
    3. Wren BW.
    The Clostridium difficile PCR ribotype 027 lineage: a pathogen on the move. Clin Microbiol Infect 2014; 20: 396–404.
    OpenUrlCrossRefPubMed
  64. 64.↵
    1. Labbé AC,
    2. Poirier L,
    3. Maccannell D,
    4. Louie T,
    5. Savoie M,
    6. Béliveau C, et al.
    Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain. Antimicrob Agents Chemother 2008; 52: 3180–3187.
    OpenUrlAbstract/FREE Full Text
  65. 65.↵
    1. Kuijper EJ,
    2. Barbut F,
    3. Brazier JS,
    4. Kleinkauf N,
    5. Eckmanns T,
    6. Lambert ML, et al.
    Update of Clostridium difficile infection due to PCR ribotype 027 in Europe, 2008. Euro Surveill 2008; 13: 18942.
    OpenUrlPubMed
  66. 66.↵
    1. He M,
    2. Miyajima F,
    3. Roberts P,
    4. Ellison L,
    5. Pickard DJ,
    6. Martin MJ, et al.
    Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nat Genet 2013; 45: 109–113.
    OpenUrlCrossRefPubMed
  67. 67.↵
    1. Wiuff C,
    2. Banks AL,
    3. Fitzpatrick F,
    4. Cottom L.
    The need for European surveillance of CDI. Adv Exp Med Biol 2018; 1050: 13–25.
    OpenUrl
  68. 68.↵
    1. Hernández-Rocha C,
    2. Barra-Carrasco J,
    3. Pizarro-Guajardo M,
    4. Ibáñez P,
    5. Bueno SM,
    6. Sarker MR, et al.
    Epidemic Clostridium difficile ribotype 027 in Chile. Emerg Infect Dis 2012; 18: 1370–1372.
    OpenUrlCrossRefPubMed
  69. 69.↵
    1. Zhang RF,
    2. Man YX,
    3. Bai YY,
    4. Shao CH,
    5. Liu CM,
    6. Wang CH, et al.
    Molecular characterization of Clostridioides difficile ribotype 027 in a major Chinese hospital. J Microbiol Immunol Infect 2021; 54: 1179–1183.
    OpenUrl
  70. 70.↵
    1. Collins DA,
    2. Hawkey PM,
    3. Riley TV.
    Epidemiology of Clostridium difficile infection in Asia. Antimicrob Resist Infect Control 2013; 2: 21.
    OpenUrl
  71. 71.↵
    1. Collins DA,
    2. Sohn KM,
    3. Wu Y,
    4. Ouchi K,
    5. Ishii Y,
    6. Elliott B, et al.
    Clostridioides difficile infection in the Asia-Pacific region. Emerg Microbes Infect 2019; 9: 42–52.
    OpenUrl
  72. 72.↵
    1. Al-Tawfiq JA,
    2. Abed MS.
    Clostridium difficile-associated disease among patients in Dhahran, Saudi Arabia. Travel Med Infect Dis 2010; 8: 373–376.
    OpenUrlPubMed
  73. 73.
    1. Alzouby S,
    2. Baig K,
    3. Alrabiah F,
    4. Shibl A,
    5. Al-Nakhli D,
    6. Senok AC.
    Clostridioides difficile infection: incidence and risk factors in a tertiary care facility in Riyadh, Saudi Arabia. J Infect Public Health 2020; 13: 1012–1017.
    OpenUrl
  74. 74.
    1. Al-Tawfiq JA,
    2. Rabaan AA,
    3. Bazzi AM,
    4. Raza S,
    5. Noureen M.
    Clostridioides (Clostridium) difficile-associated disease: epidemiology among patients in a general hospital in Saudi Arabia. Am J Infect Control 2020; 48: 1152–1157.
    OpenUrl
  75. 75.↵
    1. Aljafel NA,
    2. Al-Shaikhy HH,
    3. Alnahdi MA,
    4. Thabit AK.
    Incidence of Clostridioides difficile infection at a Saudi tertiary academic medical center and compliance with IDSA/SHEA, ACG, and ESCMID guidelines for treatment over a 10-year period. J Infect Public Health 2020; 13: 1156–1160.
    OpenUrl
  76. 76.↵
    1. Alzahrani N,
    2. Johani SA.
    Emergence of a highly resistant Clostridium difficile strain (NAP/BI/027) in a tertiary care center in Saudi Arabia. Ann Saudi Med 2013; 33: 198–199.
    OpenUrlCrossRefPubMed
  77. 77.↵
    1. Al-Thani AA,
    2. Hamdi WS,
    3. Al-Ansari NA,
    4. Doiphode SH,
    5. Wilson GJ.
    Polymerase chain reaction ribotyping of Clostridium difficile isolates in Qatar: a hospital-based study. BMC Infect Dis 2014; 14: 502.
    OpenUrl
  78. 78.↵
    1. Jamal W,
    2. Pauline E,
    3. Rotimi V.
    A prospective study of community-associated Clostridium difficile infection in Kuwait: epidemiology and ribotypes. Anaerobe 2015; 35: 28–32.
    OpenUrl
  79. 79.↵
    1. Baghani A,
    2. Mesdaghinia A,
    3. Kuijper EJ,
    4. Aliramezani A,
    5. Talebi M,
    6. Douraghi M.
    High prevalence of Clostridiodes diffiicle PCR ribotypes 001 and 126 in Iran. Sci Rep 2020; 10: 4658.
    OpenUrl
  80. 80.↵
    1. Lee HS,
    2. Plechot K,
    3. Gohil S,
    4. Le J.
    Clostridium difficile: diagnosis and the consequence of over diagnosis. Infect Dis Ther 2021; 10: 687–697.
    OpenUrl
  81. 81.↵
    1. Marler LM,
    2. Siders JA,
    3. Wolters LC,
    4. Pettigrew Y,
    5. Skitt BL,
    6. Allen SD.
    Comparison of 5 cultural procedures for isolation of Clostridium difficile from stools. J Clin Microbiol 1992; 30: 514–516.
    OpenUrlAbstract/FREE Full Text
  82. 82.
    1. Hink T,
    2. Burnham CA,
    3. Dubberke ER.
    A systematic evaluation of methods to optimize culture-based recovery of Clostridium difficile from stool specimens. Anaerobe 2013; 19: 39–43.
    OpenUrlCrossRefPubMedWeb of Science
  83. 83.↵
    1. Biasizzo M,
    2. Vadnjal S,
    3. Henigman U,
    4. Krizman M,
    5. Kirbis A,
    6. Jamnikar-Ciglenecki U.
    Development and validation of a new protocol for detecting and recovering Clostridium difficile from meat samples. J Food Prot 2018; 81: 561–568.
    OpenUrl
  84. 84.↵
    1. Perry JD.
    A decade of development of chromogenic culture media for clinical microbiology in an era of molecular diagnostics. Clin Microbiol Rev 2017; 30: 449–479.
    OpenUrlAbstract/FREE Full Text
  85. 85.↵
    1. Gateau C,
    2. Couturier J,
    3. Coia J,
    4. Barbut F.
    How to: diagnose infection caused by Clostridium difficile. Clin Microbiol Infect 2018; 24: 463–468.
    OpenUrlCrossRefPubMed
  86. 86.↵
    1. Musher DM,
    2. Manhas A,
    3. Jain P,
    4. Nuila F,
    5. Waqar A,
    6. Logan N, et al.
    Detection of Clostridium difficile toxin: comparison of enzyme immunoassay results with results obtained by cytotoxicity assay. J Clin Microbiol 2007; 45: 2737–2739.
    OpenUrlAbstract/FREE Full Text
  87. 87.↵
    1. McDonald LC,
    2. Gerding DN,
    3. Johnson S,
    4. Bakken JS,
    5. Carroll KC,
    6. Coffin SE, et al.
    Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 2018; 66: 987–994.
    OpenUrlCrossRefPubMed
  88. 88.↵
    1. Song L,
    2. Zhao M,
    3. Duffy DC,
    4. Hansen J,
    5. Shields K,
    6. Wungjiranirun M, et al.
    Development and validation of digital enzyme-linked immunosorbent assays for ultrasensitive detection and quantification of Clostridium difficile toxins in stool. J Clin Microbiol 2015; 53: 3204–3212.
    OpenUrlAbstract/FREE Full Text
  89. 89.↵
    1. Sandlund J,
    2. Davies K,
    3. Wilcox MH.
    Ultrasensitive Clostridioides difficile toxin testing for higher diagnostic accuracy. J Clin Microbiol 2020; 58: e01913–e01919.
    OpenUrl
  90. 90.↵
    1. Crobach JTM,
    2. Baktash A,
    3. Duszenko N,
    4. Kuijper EJ.
    Diagnostic guidance for C. difficile infections. [Updated 2018; 2023 Jan 15]. Available from: https://link.springer.com/chapter/10.1007/978-3-319-72799-8_3
  91. 91.↵
    1. Lessa FC,
    2. Mu Y,
    3. Bamberg WM,
    4. Beldavs ZG,
    5. Dumyati GK,
    6. Dunn JR, et al.
    Burden of Clostridium difficile infection in the United States. N Engl J Med 2015; 372: 825–834.
    OpenUrlCrossRefPubMed
  92. 92.↵
    1. Turner NA,
    2. Anderson DJ.
    Hospital infection control: Clostridioides difficile. Clin Colon Rectal Surg 2020; 33: 98–108.
    OpenUrl
  93. 93.↵
    1. Tawam D,
    2. Baladi M,
    3. Jungsuwadee P,
    4. Earl G,
    5. Han J.
    The positive association between proton pump inhibitors and Clostridium difficile infection. Innov Pharm 2021; 12: 10.
    OpenUrl
  94. 94.↵
    1. Zhang D,
    2. Prabhu VS,
    3. Marcella SW.
    Attributable healthcare resource utilization and costs for patients with primary and recurrent Clostridium difficile infection in the United States. Clin Infect Dis 2018; 66: 1326–1332.
    OpenUrlCrossRef
  95. 95.↵
    1. Perumalsamy S,
    2. Riley TV.
    Molecular epidemiology of Clostridioides difficile infections in children. J Pediatric Infect Dis Soc 2021; 10: S34–S40.
    OpenUrl
  96. 96.↵
    1. Hassoun A.
    Clostridium difficile associated disease. BMJ 2018; 363: k4369.
    OpenUrlFREE Full Text
  97. 97.↵
    1. Gupta S,
    2. Allen-Vercoe E,
    3. Petrof EO.
    Fecal microbiota transplantation: in perspective. Therap Adv Gastroenterol 2016; 9: 229–239.
    OpenUrlCrossRefPubMed
  98. 98.↵
    1. Van Nood E,
    2. Vrieze A,
    3. Nieuwdorp M,
    4. Fuentes S,
    5. Zoetendal EG,
    6. De Vos WM, et al.
    Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368: 407–415.
    OpenUrlCrossRefPubMedWeb of Science
  99. 99.↵
    1. Rao K,
    2. Safdar N.
    Fecal microbiota transplantation for the treatment of Clostridium difficile infection. J Hosp Med 2016; 11: 56–61.
    OpenUrl
  100. 100.↵
    1. Baunwall SMD,
    2. Andreasen SE,
    3. Hansen MM,
    4. Kelsen J,
    5. Høyer KL,
    6. Rågård N, et al.
    Faecal microbiota transplantation for first or second Clostridioides difficile infection (EarlyFMT): a randomised, double-blind, placebo-controlled trial. Lancet Gastroenterol Hepatol 2022; 7: 1083–1091.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords